Making cancer research accessible to patients and caregivers.
Erevna (ἔρευνα) is the Greek word for "research" or "investigation." Our mission is to bridge the gap between complex scientific publications and the people who need this information most—using AI to transform dense research papers into clear, actionable summaries.
The NIH's comprehensive database of biomedical literature, containing millions of citations from life science journals and online books.
Pre-peer-review scientific papers shared for rapid dissemination. These are clearly marked and presented with appropriate context about their preliminary nature.
The U.S. registry of clinical studies, providing information about active and completed trials for experimental treatments.
Additional sources are being reviewed and added regularly to expand our coverage.
Every article is analyzed by our AI to assess its significance and reliability. This helps you quickly understand which research findings are most relevant and how much confidence to place in them.
Breakthrough
FDA approvals, major Phase 3 successes with clear patient benefit. Rare—perhaps 1-2 per month across all cancer research.
Significant
Positive Phase 2/3 results, validated mechanisms with strong data. Represents roughly 15-20% of published research.
Incremental
Early positive signals, confirmatory studies, methodology refinements. The majority of quality research falls here.
Early Stage
Preclinical findings, basic research, hypothesis-generating studies. Important for the field but far from patient impact.
Peer-reviewed, large sample size, results replicated
Single study, smaller trial, strong preprint
Press release only, very early data, methodology concerns
Immunotherapy
Harnessing the immune system
Targeted Therapy
Precision medicine approaches
Gene Therapy
Genetic modification treatments
Screening
Early detection methods
Prevention
Risk reduction strategies
Combination
Multi-treatment approaches
Basic Research
Foundational science
Preclinical
Lab & animal studies
Phase 1
Safety testing
Phase 2
Efficacy testing
Phase 3
Large-scale trials
FDA Review
Approval process
Approved
Available to patients
Preclinical
Lab & animal studies
Phase 1
Safety testing
Phase 2
Efficacy testing
Phase 3
Large-scale trials
FDA Review
Approval process
Approved
Available to patients
Available Now
Approved treatments
1-3 Years
Late-stage trials
5+ Years
Early-stage research
Uncertain
Basic research
This is not medical advice. The information on erevna.io is intended for educational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment.
Always consult with qualified healthcare providers before making any decisions about your health or treatment options. Research findings, even breakthrough discoveries, do not immediately translate to available treatments.
If you're considering participating in a clinical trial, discuss this with your oncologist or healthcare team who can help evaluate whether it's appropriate for your specific situation.